SomaLogic shrank losses, nearly tripled revenue in runup to merger

BOULDER — SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company that went public this month in a merger with a special purpose acquisition company, saw its net losses shrink and its sales multiply in the six months ending June 30.

The company posted losses of $22.8 million in the first half of 2021, down from losses of $36.6 million during the same period last year.

Sales during the first half of the year were $38.6 million, up from $13.4 million in the year-ago period.

“Our strong first half performance reflects our team’s dedication and execution across key drivers of the business as…